As the UK races to secure its position as a global leader in advanced therapies, a growing skills gap threatens to undermine billions in investment and patient access to critical medicines. In this interview with Biopharma Boardroom, Professor Ivan W... Read more
Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 QIAGEN N.V. announced its 2026 priorities across its five... Read more
− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) – − Company Provides 2026 Combined Net Pro... Read more
Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 pres... Read more
Sharp Sterile Manufacturing has announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art facility will strengthen opportunities for highly skilled engineering and pharmaceutical manufacturing roles wi... Read more
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the... Read more
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Group, an oligonucleotide Contract Research Development and Manufacturing organization (CRDMO), t... Read more
Charles River Laboratories’ announcement of a planned leadership transition marks one of the most consequential succession moments in the global preclinical and drug development services sector in recent years. The retirement of James C. Fost... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.